


Pritumumab targets a novel antigenic on cancer cells



[Delivering human antibodies for the treatment of cancer](#)

Pritumumab

[Learn more about Nascent Biotech's primary drug product, Pritumumab.](#)

NBIO Stock Information

NBIO: (%)

Investor Presentation

[Download Investor Presentation](#)

Email Updates

[Subscribe Now](#)

Latest News

JUNE 3, 2019

[Nascent CEO Sean Carrick On RedChip Money Report](#)

MARCH 10, 2019

[Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises](#)

DECEMBER 11, 2018

[Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer](#)

JULY 27, 2018


[Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG \(Pritumumab\)](#)

APRIL 4, 2018

[Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference](#)

Pritumumab

is a proprietary monoclonal antibody (mAb)



Delivering human antibodies for **the treatment of cancer**

Pritumumab

[Learn more about Nascent Biotech's primary drug product, Pritumumab.](#)

NBIO Stock Information

NBIO: (%)

Investor Presentation

[Download Investor Presentation](#)

Email Updates

[Subscribe Now](#)

Latest News

JUNE 3, 2019

[Nascent CEO Sean Carrick On RedChip Money Report](#)

MARCH 10, 2019

[Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises](#)

DECEMBER 11, 2018

[Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer](#)


JULY 27, 2018

[Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG \(Pritumumab\)](#)

APRIL 4, 2018

[Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference](#)

Pritumumab has cured a rare form of brain cancer



Delivering human antibodies for **the treatment of cancer**

Pritumumab

[Learn more about Nascent Biotech's primary drug product, Pritumumab.](#)

NBIO Stock Information

NBIO: (%)

Investor Presentation

[Download Investor Presentation](#)

Email Updates

[Subscribe Now](#)

Latest News

JUNE 3, 2019

Nascent CEO Sean Carrick On RedChip Money Report

MARCH 10, 2019

Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

DECEMBER 11, 2018

Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer


JULY 27, 2018:

Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)

APRIL 4, 2018

Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference

Pritumumab has received FDA orphan drug status



Delivering human antibodies for **the treatment of cancer**

Pritumumab

[Learn more about Nascent Biotech's primary drug product, Pritumumab.](#)

NBIO Stock Information

NBIO: (%)

Investor Presentation

[Download Investor Presentation](#)

Email Updates

[Subscribe Now](#)

Latest News

JUNE 3, 2019

[Nascent CEO Sean Carrick On RedChip Money Report](#)

MARCH 10, 2019

[Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises](#)

DECEMBER 11, 2018

[Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer](#)


JULY 27, 2018

[Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG \(Pritumumab\)](#)

APRIL 4, 2018

[Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference](#)

Pritumumab has begun clinical toxicology trials



Delivering human antibodies for **the treatment of cancer**

Pritumumab

[Learn more about Nascent Biotech's primary drug product, Pritumumab.](#)

NBIO Stock Information

NBIO: (%)

Investor Presentation

[Download Investor Presentation](#)

Email Updates

[Subscribe Now](#)

Latest News

JUNE 3, 2019

Nascent CEO Sean Carrick On RedChip Money Report

MARCH 10, 2019

Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises

DECEMBER 11, 2018

Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer

JULY 27, 2018

Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)

APRIL 4, 2018

Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference

Pritumumab by Nascent Biotech

Nascent Biotech's lead product, Pritumumab, a natural human antibody, has been used to treat 250 brain cancer patients.

After 5 years, patients treated with pritimumab have an overall survival rate of 25-30%, compared to 3% standard therapy, demonstrating antibodies are safe and effective.

The United States Patent Office has issued 11 patents for Pritumumab: 4618577; 4761377; 5093261; 5155036; 5286647; 5589573; 5602027; 6051229; 6051387; 6051693; 6165467.

Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer.

The recognized target is ecto-domain vimentin that is expressed on the cell surface of a variety of adenocarcinomas, including brain cancers and melanoma, but not expressed by normal tissues and cells.

In various Phase II clinical trials in Japan patients with brain cancer treated with pritimumab showed an overall response rate between 25–30% with several survivors beyond 5-years post-treatment. Toxicities were minimal suggesting pritimumab is a safe and effective therapeutic agent for the treatment of patients with brain cancer.

GET THE NASCENT NEWSLETTER

Stay in touch with news from Nascent Biotech when you sign up for our free newsletter.

CONTACT NASCENT

Communicate with Nascent Biotech the quick and easy way – through our contact form.

[Contact Nascent](#)

NACENT HEADLINES

JUNE 3, 2019

[Nascent CEO Sean Carrick On RedChip Money Report](#)

MARCH 10, 2019

[Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and promises](#)

DECEMBER 11, 2018

[Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer](#)